Summary
| Direction in Lyme Disease | ↕ Inconsistent — reported as both higher and lower across studies, with no consistent direction |
|---|---|
| Category | Molecular |
| Also described as | Molecular detection |
| Compared against | Uninfected |
| Associated symptoms | Low sensitivity in blood; higher in EM biopsy |
| Test type | Clinical or physiological test |
| Source | Lantos et al. 2021 — doi:10.1093/cid/ciaa1215 |
| Condition atlas | Lyme Disease Biomarker Atlas |
Trials, interventions and tests
In clinical-trial registrations this marker maps to the outcome term Concentration of Viral RNA in Adipose Tissue (9 registered trials use a matching outcome measure).
Clinical trials using B. burgdorferi PCR (blood/CSF/tissue) as an outcome
1 more trials reference this marker.
Commercial test availability
Borrelia burgdorferi PCR — commercial laboratory test.
Links are for reference only; availability, specimen requirements and coverage vary by location.
Related Molecular markers in Lyme Disease
Full list: Lyme Disease Biomarker Atlas.
Frequently asked questions
Is B. burgdorferi PCR (blood/CSF/tissue) high or low in Lyme Disease?
Mixed. Some studies report higher and others lower B. burgdorferi PCR (blood/CSF/tissue) in Lyme Disease compared with Uninfected, so no single direction is established. Source: Lantos et al. 2021.
What symptoms is B. burgdorferi PCR (blood/CSF/tissue) associated with in Lyme Disease?
The cited literature associates this marker with Low sensitivity in blood; higher in EM biopsy. These are population-level associations and do not mean the marker causes the symptoms.
Which test measures B. burgdorferi PCR (blood/CSF/tissue)?
It is measured as a clinical or physiological test. Commercial laboratories such as LabCorp, Quest Diagnostics list an orderable assay.
Is one abnormal B. burgdorferi PCR (blood/CSF/tissue) result diagnostic of Lyme Disease?
No. No single biomarker is diagnostic of Lyme Disease. B. burgdorferi PCR (blood/CSF/tissue) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.
Cite this page
Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.